Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Cells from the Research Institute of the MUHC on the road to China

The diabetes epidemic is devastating many areas of the world. In China, approximately 20 million people suffer from the disease - and the number keeps growing. To meet this massive health challenge, the Chinese government is encouraging researchers from all over the world to collaborate with Chinese scientists in the development of effective diabetes therapies.

To fund an innovative Quebec-Chinese research initiative in this area, the Ministère du Développement économique, de l'Innovation et de l'Exportation from Quebec recently awarded a grant of $150,000 to Dr. Constantin Polychronakos of the Research Institute of the McGill University Health Centre (MUHC) in Montreal.

The funding will be used to establish a partnership with Dr. Du, Director of the Pharmacology Institute of the Chinese Academy of Medical Sciences in Beijing. The collaboration will focus on a new therapeutic approach to preventing type 2 diabetes.

Contrary to popular belief, the pancreas is not the only insulin-producing organ of the body. The thymus also produces a small quantity of insulin. While insufficient to regulate blood glucose levels, this insulin "programs" the immune system to recognize the peptide as "self." In healthy people, this programming prevents pancreatic insulin from being destroyed by an immune reaction. Dr. Polychronakos has studied this mechanism for many years and has succeeded in creating a culture line of insulin-producing thymus cells.

... more about:
»Diabetes »Hospital »Insulin »Montreal »Polychronakos

His goal is to find a drug that would trigger these cells to secrete more insulin. This would theoretically increase the body's tolerance to the hormone and thus reduce the symptoms of diabetes. However, achieving this objective means testing approximately 100,000 different compounds with special high-performance drug screening equipment-precisely the technology that is available in Dr. Du's laboratory in Beijing.

The collaboration between Dr. Polychronakos and Dr. Du will allow each one to benefit from the other's technology. Their research initiative has enormous potential and international scope. The project is expected to get underway no later than fall, 2008.

Dr. Constantin Polychronakos is Director of the MUHC's Pediatric Endocrinology and Metabolism Division, Co-Leader of the Endocrinology, Diabetes, Nutrition and Kidney Diseases Axes of the Research Institute of the MUHCand Professor of Pediatrics and Human Genetics at McGill University.

This project is co-funded by the Ministère du Développement économique, de l'Innovation et de l'Exportation, the Juvenile Diabetes Research Foundation, and the Government of the People's Republic of China.

The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University--the Montreal Children's, Montreal General, Royal Victoria, and Montreal Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge.

The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at McGill University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.
The Research Institute of the MUHC is supported in part by the Fonds de la recherche en santé du Québec.

For further details visit:

The Montreal Children's Hospital is the pediatric teaching hospital of the McGill University Health Centre (MUHC). The institution is a leader in the care and treatment of sick infants, children, and adolescents from across Quebec. The Montreal Children's Hospital provides a high level and broad scope of health care services, and provides ultra specialized care in many fields including: cardiology and cardiac surgery; neurology and neurosurgery, traumatology; genetic research; psychiatry and child development and musculoskeletal conditions, including orthopedics and rheumatology. Fully bilingual and multicultural, the institution respectfully serves an increasingly diverse community in more than 50 languages.

For more information please contact:

Isabelle Kling
Communications Coordinator (research)
MUHC Public Relations and Communications
(514) 934-1934 #36419

Isabelle Kling | MUHC
Further information:

Further reports about: Diabetes Hospital Insulin Montreal Polychronakos

More articles from Life Sciences:

nachricht North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich

nachricht Researchers Discover New Anti-Cancer Protein
22.03.2018 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Modular safety concept increases flexibility in plant conversion

22.03.2018 | Trade Fair News

New interactive map shows climate change everywhere in world

22.03.2018 | Earth Sciences

New technologies and computing power to help strengthen population data

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>